Clinical Trials Directory

Trials / Completed

CompletedNCT00652834

Small Bowel Capsule Endoscopy Findings in Patients Receiving Cellcept®

Gastrointestinal Mucosal Findings in Patients Receiving Mycophenolic Acid (MPA) as Demonstrated by Small Bowel Capsule Endoscopy (SBCE)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
23 (actual)
Sponsor
University of California, Los Angeles · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to learn more about symptoms and gastrointestinal lesions associated with taking myfortic® by switching patients to a delayed release formulation that is developed to alleviate GI symptoms. A comparison of the frequency and severity of GI symptoms observed in patients treated with MMF (cellcept®) after conversion to myfortic® will be measured by using a self-assessed questionnaire called Gastrointestinal Symptom Rating Scale (GSRS). To prove the incidence and improvement of GI lesions in patients treated with MMF (cellcept®) after conversion to myfortic® will be measured by using Small Bowel Capsule Endoscopy (SBCE).

Detailed description

Myfortic® recently introduced to the market has shown to be similar to MMF in how effectively it works and how well it is tolerated. Both drugs have the same active ingredient, but they are different in the way that they deliver them to the body. Myfortic® is an advanced, enteric coated formulation of mycophenolate sodium (EC-MPS) that delays the release of the active ingredient, MPA. MPA has more potent effects on the lymphocytes than other cells. This makes for improved GI tolerability of the MPA therapy.

Conditions

Interventions

TypeNameDescription
PROCEDURESmall bowel capsule endoscopy (SBCE)SBCE will be performed at Day 2 and Day 30.
DRUGmyforticswitching from mycophenolate mofetil to mycophenolic acid on equimolar basis

Timeline

Start date
2009-04-01
Primary completion
2011-03-01
Completion
2011-05-01
First posted
2008-04-04
Last updated
2016-03-04
Results posted
2016-03-04

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00652834. Inclusion in this directory is not an endorsement.